查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
心肌炎疾病市場報告：2030 年趨勢、預測與競爭分析
市場調查報告書
商品編碼
1356863

心肌炎疾病市場報告：2030 年趨勢、預測與競爭分析

Myocarditis Disease Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

心肌炎的趨勢和預測

預計到 2030 年，全球心肌炎市場將達到 19.3 億美元，2024 年至 2030 年年複合成長率為 5.6%。該市場的主要促進因素是慢性病患病的增加、醫療基礎設施投資的增加以及老年人口的增加。全球心肌炎市場前景廣闊，醫院、專科診所和居家醫療市場蘊藏商機。

心肌炎疾病依部位分類

該研究包括按類型、治療方法、診斷、最終用途和地區對全球心肌炎疾病的預測。

心肌炎疾病相關企業名單

市場上的公司根據其提供的產品品質進行競爭。該市場的主要企業專注於擴大製造設施、投資研發、開拓基礎設施以及利用整個價值鏈的整合機會。這些策略使心肌炎公司能夠滿足不斷成長的需求，確保競爭力，開發創新產品和技術，降低製造成本，並擴大基本客群。本報告中涉及的心肌炎治療藥物的公司簡介如下。

  • F·霍夫曼·拉羅什
  • 邁蘭公司
  • 梯瓦製藥工業公司
  • 賽諾菲
  • 輝瑞公司
  • 葛蘭素史克
  • 諾華公司
  • 茲杜斯·卡迪拉
  • 阿斯利康
  • 強生公司

心肌炎疾病

  • Lucintel 預測，慢性心肌炎將在預測期內出現最高成長。
  • 醫院仍然是最大的部分。
  • 由於心血管疾病患者數量的增加、醫療基礎設施的持續發展以及老年人口的增加，預計亞太地區在預測期內將出現最高的成長。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要要素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些，由於材料或產品替代導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球心肌炎疾病市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球心肌炎疾病市場趨勢（2018-2023）與預測（2024-2030）
  • 按類型分類的全球心肌炎疾病市場
    • 急性心肌炎
    • 慢性心肌炎
    • 淋巴球性心肌炎
  • 按治療分類的全球心肌炎疾病市場
    • 藥品
    • 外科手術
    • 其他
  • 全球心肌炎疾病市場（按診斷）
    • 驗血
    • 影像檢查
    • 心導管
    • 心肌切片檢查
    • 其他
  • 全球心肌炎疾病市場（依最終用途）
    • 醫院
    • 專科診所
    • 居家護理
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球心肌炎疾病市場（按地區）
  • 北美心肌炎疾病市場
  • 歐洲心肌炎疾病市場
  • 亞太心肌炎疾病市場
  • 其他區域性心肌炎疾病市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按類型分類的全球心肌炎疾病市場成長機會
    • 全球心肌炎疾病治療市場成長機會
    • 全球心肌炎疾病市場診斷成長機會
    • 全球心肌炎疾病市場成長機會（依最終用途）
    • 全球心肌炎疾病市場成長機會（按地區）
  • 全球心肌炎疾病市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球心肌炎疾病市場的產能擴張
    • 全球心肌炎疾病市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • F. Hoffmann-La Roche
  • Mylan NV
  • Teva Pharmaceutical Industries
  • Sanofi
  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Zydus Cadila
  • AstraZeneca
  • Johnson & Johnson
簡介目錄

Myocarditis Disease Trends and Forecast

The future of the global myocarditis disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global myocarditis disease market is expected to reach an estimated $1.93 billion by 2030 with a CAGR of 5.6% from 2024 to 2030. The major drivers for this market are increasing prevalence of chronic disorders, increasing investment for healthcare infrastructure ,and growing number of geriatric population.

A more than 150-page report is developed to help in your business decisions.

Myocarditis Disease by Segment

The study includes a forecast for the global myocarditis disease by type, treatment, diagnosis, end use, and region.

Myocarditis Disease Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Acute Myocarditis
  • Chronic Myocarditis
  • Lymphocytic Myocarditis

Myocarditis Disease Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Surgery
  • Others

Myocarditis Disease Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Tests
  • Imaging Tests
  • Cardiac Catheterization
  • Heart Muscle Biopsy
  • Others

Myocarditis Disease Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Myocarditis Disease Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Myocarditis Disease Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies myocarditis disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the myocarditis disease companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Mylan N.V.
  • Teva Pharmaceutical Industries
  • Sanofi
  • Pfizer
  • Glaxosmithkline
  • Novartis
  • Zydus Cadila
  • Astrazeneca
  • Johnson & Johnson

Myocarditis Disease

  • Lucintel forecasts that chronic myocarditis is expected to witness highest growth over the forecast period.
  • Hospital will remain the largest segment.
  • APAC is expected to witness highest growth over the forecast period due to growing cases of cardiovascular diseases, on-going development of healthcare infrastructure, and rising geriatric population in this region.

Features of the Global Myocarditis Disease Market

  • Market Size Estimates: Myocarditis Disease Market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Myocarditis Disease Market by various segments, such as by type, treatment, diagnosis, end use and region in terms of($B).
  • Regional Analysis: Myocarditis Disease Market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, treatments, diagnosis, end uses, and region.s for the myocarditis disease market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the myocarditis disease market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the myocarditis disease market size?

Answer: The global myocarditis disease market is expected to reach an estimated $1.93 billion by 2030.

Q.2. What is the growth forecast for myocarditis disease market?

Answer: The global myocarditis disease market is expected to grow with a CAGR of 5.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the myocarditis disease market?

Answer: The major drivers for this market are increasing prevalence of chronic disorders, increasing investment for healthcare infrastructure, and growing number of geriatric population .

Q.4. What are the major segments for myocarditis disease market?

Answer: The future of the myocarditis disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key myocarditis disease market companies?

Answer: Some of the key myocarditis disease companies are as follows:

  • F. Hoffmann-La Roche
  • Mylan N.V.
  • Teva Pharmaceutical Industries
  • Sanofi
  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Zydus Cadila
  • AstraZeneca
  • Johnson & Johnson

Q.6. Which myocarditis disease market segment will be the largest in future?

Answer: Lucintel forecasts that chronic myocarditis is expected to witness highest growth over the forecast period.

Q.7. In myocarditis disease market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to growing cases of cardiovascular diseases, on-going development of healthcare infrastructure, and rising geriatric population in this region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the myocarditis disease market by type (acute myocarditis, chronic myocarditis, and lymphocytic myocarditis), treatment (medication, surgery, and others), diagnosis (blood tests, imaging tests, cardiac catheterization, heart muscle biopsy, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Myocarditis Disease Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Myocarditis Disease Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Myocarditis Disease Market by Type
    • 3.3.1: Acute Myocarditis
    • 3.3.2: Chronic Myocarditis
    • 3.3.3: Lymphocytic Myocarditis
  • 3.4: Global Myocarditis Disease Market by Treatment
    • 3.4.1: Medication
    • 3.4.2: Surgery
    • 3.4.3: Others
  • 3.5: Global Myocarditis Disease Market by Diagnosis
    • 3.5.1: Blood Tests
    • 3.5.2: Imaging Tests
    • 3.5.3: Cardiac Catheterization
    • 3.5.4: Heart Muscle Biopsy
    • 3.5.5: Others
  • 3.6: Global Myocarditis Disease Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Homecare
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Myocarditis Disease Market by Region
  • 4.2: North American Myocarditis Disease Market
    • 4.2.4: North American Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Myocarditis Disease Market
    • 4.3.1: European Myocarditis Disease Market by Type: Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis
    • 4.3.2: European Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Myocarditis Disease Market
    • 4.4.1: APAC Myocarditis Disease Market by Type: Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis
    • 4.4.2: APAC Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Myocarditis Disease Market
    • 4.5.1: ROW Myocarditis Disease Market by Type: Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis
    • 4.5.2: ROW Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Myocarditis Disease Market by Type
    • 6.1.2: Growth Opportunities for the Global Myocarditis Disease Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Myocarditis Disease Market by Diagnosis
    • 6.1.4: Growth Opportunities for the Global Myocarditis Disease Market by End Use
    • 6.1.5: Growth Opportunities for the Global Myocarditis Disease Market by Region
  • 6.2: Emerging Trends in the Global Myocarditis Disease Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Myocarditis Disease Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Myocarditis Disease Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Mylan N.V.
  • 7.3: Teva Pharmaceutical Industries
  • 7.4: Sanofi
  • 7.5: Pfizer
  • 7.6: GlaxoSmithKline
  • 7.7: Novartis
  • 7.8: Zydus Cadila
  • 7.9: AstraZeneca
  • 7.10: Johnson & Johnson